Depending on the dosage regimen and study population, supplementation with either form may augment total serum 25(OH)D concentrations [8] [9] [10] [11] [12] [13] [14] [15] [16] , and correlate with efficacy [17] [18] [19] . Several reports have demonstrated that vitamin D 2 is less potent than vitamin D 3 in raising serum 25(OH)D concentrations; [8, 10, [20] [21] [22] [23] [24] [25] [26] whereas, other reports demonstrate equipotency [9, 13] 
Introduction
Vitamin D deficiency, as determined by serum concentrations of 25(OH)D [ie., the sum of 25(OH)D 3 and 25(OH)D 2 ] is known to compromise musculoskeletal health [1, 2] . This knowledge has spurred an increase in demand for 25(OH)D testing which has led many laboratories to replace radioactive methods with fully automated immunoassays. The term "Vitamin D" represents a family of related secosteroids whose parent compound exists in two forms-one made by skin exposed to UVB sun rays (cholecaliferol, vitamin D 3 ) and the other made by plants, fungi, and fish (ergocalciferol, vitamin D 2 ) [1, 3] . Both forms of vitamin D undergo identical hydroxylations to yield 25- [4] and disease states that respond to supplementation [1, 2, [5] [6] [7] . Nutritional supplements may contain either vitamin D 3 or vitamin D 2 forms [2] . Depending on the dosage regimen and study population, supplementation with either form may augment total serum 25(OH)D concentrations [8] [9] [10] [11] [12] [13] [14] [15] [16] , and correlate with efficacy [17] [18] [19] . Several reports have demonstrated that vitamin D 2 is less potent than vitamin D 3 in raising serum 25(OH)D concentrations; [8, 10, [20] [21] [22] [23] [24] [25] [26] whereas, other reports demonstrate equipotency [9, 13] .
How vitamin D 2 supplementation affects endogenous 25(OH)D 2 , 25(OH)D 3 and total 25(OH)D has been the subject of several studies in recent years. Some reports demonstrate a compensatory decline in 25(OH)D 3 serum concentrations concomitant with an increase in 25(OH)D 2 serum concentrations compared to baseline [8, 10, 23, 27] . Peak concentrations of serum 25(OH)D after dosing were found to be variable-greater [8] , lower [23] , or not changed [13, 27] . The variable results likely reflect differences in study design that include dosing regimen, study population, season, and latitude. Endogenous 25(OH)D 2 concentrations are generally very low (less than five percent of total serum 25(OH)D concentrations); however, the 25(OH)D 2 to 25(OH)D 3 ratio may change substantially after vitamin D 2 supplementation [8, 10, 11, 13, 23, 27] . Thus, current guidelines for the measurement of total serum 25(OH)D concentrations stipulate that assays must recognize serum 25(OH)D 3 and 25(OH)D 2 in equimolar amounts in order to avoid underrepresentation and misdiagnosis of total serum 25(OH)D concentrations [28] .
In the past, variability was reported in the ability of automated immunoassays to accurately measure serum 25(OH)D 2 concentrations [29] [30] [31] [32] . The affinity for 25(OH)D 2 and other vitamin D metabolites was found to differ between assays, which-depending on the assay-reportedly overestimated [29, 30, 32] [29, 32] , and Roche ELECSYS Vitamin D Total (Roche Diagnostics, Mannheim, Germany) assays [29] . The DiaSorin LIAISON 25 OH Vitamin D TOTAL assay (DiaSorin, Stillwater, MN, USA) has been reported to over-recover [32] and under-recover [29, 30, 33] 25(OH)D 2 concentrations, depending on the study.
The goal of this study was to evaluate the ability of four current Vitamin D Total immunoassays (from Siemens, DiaSorin, Abbott, and Roche) by comparison with a VDSCP-certified ID-LC-MS/MS method traceable to NIST to accurately measure and monitor serum total 25(OH)D concentrations in serum samples from subjects receiving vitamin D 2 supplementation.
Materials and methods

Sample population and study design
One hundred and forty seven (147) archived and non-identifiable clinical serum samples from 23 apparently healthy adult donors were purchased from a commercial vendor (Research Sample Bank, Inc., Delay Beach, FL, USA). Written informed consent was obtained from all participants. One subject withdrew from the study before, and two others withdrew from the study after the first monthly blood draw. Thus, results are presented for those 20 subjects that completed the study (total of 140 samples). The Roche ELECSYS Vitamin D Total assay and Abbott ARCHITECT 25-OH Vitamin D assay, each measured 25(OH)D concentrations in 139 total samples due to loss of one sample after the first month. ID-LC-MS/MS results at baseline confirmed virtually undetectable serum concentrations of 25(OH)D 2 . The average age for the 20 remaining subjects at the end of the study was 41 years (range 22-72 years). Seven subjects were females and 13 subjects were males. All subjects initiated the study between April 16, 2013 and April 17, 2013 and ended the study between October 15, 2013 and November 27, 2013. Blood was drawn from 23 healthy donors-not previously vitamin D supplemented-at baseline and at approximately 1, 2, 3, 4, 5, and 6 months after supplementation with ergocalciferol, vitamin D2-2400 IU daily by oral route (Deva Vegan Vitamins Vegan vitamin D2, DEVA Nutrition LLC, info@devanutrition.com). After collection, blood was placed at 4°C, centrifuged, and serum aliquots were prepared. Serum samples were stored at −20°C for less than nine months until they were sent to Siemens Healthcare Diagnostics Inc. ( 
Method comparison and traceability
Three of the assays evaluated in this study are competitive chemiluminescent immunoassays-Siemens ADVIA Centaur assay [34] , DiaSorin LIAISON assay [35] , and Abbott ARCHITECT assay [36] . The Roche ELECSYS Vitamin D Total assay is an electrochemiluminescence protein assay that involves capture of 25(OH)D by vitamin D binding protein [37] . Traceability of the assays can be found in the manufacturer's Instructions for Use as to the performance of the assays.
ADVIA Centaur assay
[34] The assay is traceable to the Ghent University 25(OH)vitamin D Reference Measurement Procedure (RMP) and has also achieved certification from the CDC-VDSCP [28, [38] [39] [40] . When this study was performed the ADVIA Centaur Vitamin D Total assay was the only assay of the ones tested that was CDC-VDSCP certified. [41] the total CVs were in the range of 12.6-10.8% (19.8-280 .0 nmol/L, 7.9-112.1 ng/mL,) for serum and 9.7-9.5% (45.0-154.5 nmol/L, 18.0-61.8 ng/mL) for kit controls.
Isotope dilution liquid chromatography mass spectrometry (ID-LC-MS/MS)
The serum 
Statistics
Correlation plots, difference plots, Bland-Altman plots, and bias + standard deviation (SD) values were obtained using GraphPad Prism and Microsoft Excel (2010); Analyze-It add-in program in Excel was used to compare the different sets of data in order to obtain the 95% confidence interval (CI), 95% limits of agreement, and Deming fit.
Results
The ID-LC-MS/MS method was used to measure endogenous concentrations of serum 25 Fig. 1 ). At two months, serum 25(OH)D 2 and 25(OH)D 3 concentrations exhibited a 1:1 ratio and remained at their two-month concentrations until the end of the six-month study. The total serum 25(OH)D concentrations rose above those at baseline, reaching equilibrium by one month (Table 1 and Fig. 1 ).
The total 25(OH)D concentrations measured by the ADVIA Centaur assay and LIAISON assay, but not the ARCHITECT assay and ELECSYS assay, were greater than baseline in subjects taking supplements for one month. The ARCHITECT assay and ELECSYS assay results remained at baseline concentrations throughout the study ( Table 1) .
The ability of the four Vitamin D Total assays to accurately measure and monitor total serum 25(OH)D concentrations over a six-month period compared to the ID-LC-MS/MS method was determined. The (Fig. 2) .
The mean percent bias comparing each of the immunoassays to the ID LC-MS/MS assay was similar: ADVIA Centaur assay, − 7.1 + 9.3%, ELECSYS assay, − 8.4 + 18.0%; LIAISON assay, − 15.3 + 14.0%; and ARCHITECT assay, − 16.3 + 14.2% (data not shown). The results for overall average bias, overall average percent bias, along with 95% limits of agreement plotted as a function of total serum 25(OH)D 2 concentrations are shown in Fig. 3 .
In order to compare the bias in samples containing relatively low 25(OH)D 2 concentrations (mainly those samples at baseline) with bias in samples containing greater concentrations of 25(OH)D 2 , results were analyzed by month ( Table 1 ). The percent bias to ID-LC-MS/MS at each of the time-points demonstrated a negative trend for the LIAISON, ELECSYS, and ARCHITECT assays, and a slight positive trend for the ADVIA Centaur assay (Table 1, Fig. 3 ).
Not unexpected, the results of assay comparisons to Bland Altman were similar to those of ID-LC-MS/MS: ADVIA Centaur assay, −7.8 + 10% versus −7.1 + 9.3%, ELECSYS assay, −10. [42] . According to this criterion, the ADVIA Centaur assay, ELECSYS assay, and LIAISON assay results met the minimum performance goal for comparisons to ID-LC-MS/MS results.
Three participants did not show the typical increases observed in serum 25(OH)D 2 concentrations compared to baseline (ie., they did not achieve 25 [15, 18] .) The 20.0 nmol/L (8.0 ng/mL) mean increment is similar to the 15.0-17.5 nmol/L (6.0-7.0 ng/mL) increase in circulating 25(OH)D generally found for 1000 IU daily vitamin D 3 dosing [12, 16, 46] . Heaney et al. [12] showed that healthy subjects [with a basal total serum 25(OH)D concentrations of 72 nmol/L (28.8 ng/mL) and 65.6 nmol/L (26.24 ng/mL) who were receiving 25.0 and 250.0 μg (1000 to 10,000 IU) daily vitamin D 3 ] could increase their total 25(OH)D concentrations by 12.0 and 158 nmol/L (4.8 and 63.4 ng/mL) after five months, respectively. Thus, it is possible that higher than a 2400 IU daily dose of vitamin D 2 could have led to greater total serum 25(OH)D concentrations in these healthy individuals. The continuous daily dosing time-to-equilibrium for total serum 25(OH)D concentrations was about one month-faster than the five months reported for a 1000 IU daily dose of 25(OH)D 3 [12] .
We do not know if 2,400 IU daily of vitamin D 2 would increase 25(OH)D concentrations in vitamin D deficient adults (b50.0 nmol/L, b 20.0 ng/mL,) into the optimal range; this was not a goal of the study.
However, we surmise that 2,400 IU daily may not be sufficient based on the results of several studies-albeit those studies used different regimens of vitamin D 2 or vitamin D 3 [13, 46] -and the Endocrine Society guidelines that recommend initial treatment of vitamin D deficient adults with vitamin D 2 or vitamin D 3 doses of 50,000 IU once a week or 6000 IU per day to achieve a blood concentration of 25(OH)D above 30.0 ng/mL [2] .
In the present study, 2400 IU daily of vitamin D 2 led to higher serum 25(OH)D 2 concentrations and lower serum 25(OH)D 3 concentrations than baseline; total serum 25(OH)D concentrations were higher than baseline. These compensatory findings are consistent with the results of others; [8, 10, 23, 27] whereas, total serum 25(OH)D concentrations were reported to be higher [8] , lower [23] , or unchanged in those studies [13, 27] [8, 47] .
Vitamin D 2 metabolites appear to be less effective at increasing serum 25(OH)D concentrations, especially when given as a bolus dose compared with daily dosing [8, 10, [20] [21] [22] [23] [24] [25] [26] 48, 49] . The present study did not directly compare the efficacy of vitamin D 2 and vitamin D 3 , so we do not know whether a similar daily dose of 25(OH)D 3 would have subjects' diets would have changed such that serum 25(OH)D 2 and total serum 25(OH)D concentrations would rise as quickly as they did within the first few weeks concomitant with a decline in 25(OH)D 3 serum concentrations. In addition, samples were collected in spring/early summer making it unlikely that vitamin D 3 concentrations would decline due to lack of exposure to sunlight. Third, serum PTH and calcium concentrations were not measured. Serum 25(OH)D concentrations regulate physiological concentrations of serum PTH [12, 45] . The highest total serum 25(OH)D concentration measured in this study by ID-LC-MS/MS was 167.3 nmol/L (68 ng/mL) which was reported to be within the safe range for maintaining serum PTH and calcium concentrations (b220.0 nmol/L, b 88.0 ng/mL) [16, 18] . Future studies will include serum PTH and calcium measurements. The strengths of the study include adequate number of samples representative of apparently healthy subjects receiving vitamin D 2 (D 2 :D 3 ratio of 1:1); relatively long study (6 months); good participant compliance with protocol; use of a comparison VDSCP-certified ID-LC-MS/MS method traceable to NIST; use of at least one assay, ADVIA Centaur Vitamin D Total assay, traceable to the Ghent University 25(OH)vitamin D RMP that has also achieved certification by the CDC VDSCP.
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Conclusions
The 25(OH)D bias results for the ADVIA Centaur assay and ELECSYS assay were slightly lower than those for the LIAISON assay and the ARCHITECT assay; however, this study demonstrated that all 25(OH)D assays achieved acceptable performance.
